CA2963941C - Mri imaging of amyloid plaque using liposomes - Google Patents

Mri imaging of amyloid plaque using liposomes Download PDF

Info

Publication number
CA2963941C
CA2963941C CA2963941A CA2963941A CA2963941C CA 2963941 C CA2963941 C CA 2963941C CA 2963941 A CA2963941 A CA 2963941A CA 2963941 A CA2963941 A CA 2963941A CA 2963941 C CA2963941 C CA 2963941C
Authority
CA
Canada
Prior art keywords
alkyl
liposomal composition
phospholipid
substituted
aromatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2963941A
Other languages
English (en)
French (fr)
Other versions
CA2963941A1 (en
Inventor
Eric A. Tanifum
Mayank Srivastava
Ananth Annapragada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Texas Children's Hospital
Original Assignee
Texas Children's Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas Children's Hospital filed Critical Texas Children's Hospital
Publication of CA2963941A1 publication Critical patent/CA2963941A1/en
Application granted granted Critical
Publication of CA2963941C publication Critical patent/CA2963941C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
    • A61K49/0084—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion liposome, i.e. bilayered vesicular structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/126—Linear polymers, e.g. dextran, inulin, PEG

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2963941A 2014-10-08 2015-10-08 Mri imaging of amyloid plaque using liposomes Active CA2963941C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462061514P 2014-10-08 2014-10-08
US62/061,514 2014-10-08
US201562111057P 2015-02-02 2015-02-02
US62/111,057 2015-02-02
PCT/US2015/054732 WO2016057812A1 (en) 2014-10-08 2015-10-08 Mri imaging of amyloid plaque using liposomes

Publications (2)

Publication Number Publication Date
CA2963941A1 CA2963941A1 (en) 2016-04-14
CA2963941C true CA2963941C (en) 2023-08-01

Family

ID=55653789

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2963941A Active CA2963941C (en) 2014-10-08 2015-10-08 Mri imaging of amyloid plaque using liposomes

Country Status (10)

Country Link
US (4) US9744251B2 (enExample)
EP (3) EP3542828A1 (enExample)
JP (1) JP6505235B2 (enExample)
KR (1) KR102409017B1 (enExample)
CN (1) CN107106708B (enExample)
AU (2) AU2015330824A1 (enExample)
CA (1) CA2963941C (enExample)
ES (2) ES3032054T3 (enExample)
MX (1) MX371295B (enExample)
WO (1) WO2016057812A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9801957B2 (en) 2011-04-06 2017-10-31 Ananth Annapragada Lipid-based nanoparticles
EP2756459B1 (en) 2012-01-20 2020-12-09 Ananth Annapragada Methods and compositions for objectively characterizing medical images
EP3542828A1 (en) 2014-10-08 2019-09-25 Texas Children's Hospital Mri imaging of amyloid plaque using liposomes
EP3487545A1 (en) 2016-07-22 2019-05-29 AC Immune S.A. Compounds for imaging tau protein aggregates
WO2018015549A1 (en) 2016-07-22 2018-01-25 Ac Immune S.A. Compounds for imaging tau protein aggregates
US11052162B2 (en) 2016-09-16 2021-07-06 Texas Children's Hospital Liposomal gadolinium (GD) contrast agent “NMRX” for T1-MRI
EP3548002B1 (en) 2016-11-30 2025-04-30 Texas Children's Hospital Hydrophilic fluorinated molecules for liposomal 19f mri probes with unique mr signatures
EP3743426A1 (en) 2018-01-24 2020-12-02 AC Immune SA Azacarboline compounds for the detection of tau aggregates
WO2019145291A1 (en) 2018-01-24 2019-08-01 Ac Immune Sa Gamma-carboline compounds for the detection of tau aggregates
CN116173238A (zh) * 2018-03-29 2023-05-30 微脉管治疗有限公司 用于检测和治疗阿尔茨海默病的组合物及方法
WO2019234243A1 (en) 2018-06-08 2019-12-12 Ac Immune Sa Novel compounds for diagnosis
JP7545393B2 (ja) * 2019-01-24 2024-09-04 アルゼカ バイオサイエンシズ、エルエルシー 誤って折りたたまれたタンパク質を画像化するための機能化リポソーム
CN114341364B (zh) * 2019-07-08 2025-07-18 阿尔兹卡生物科学公司 Tau病理靶向配体
US11614451B2 (en) 2019-07-08 2023-03-28 Alzeca Biosciences, LLC Targeting ligands for tau pathology
KR102546470B1 (ko) * 2020-01-29 2023-06-21 텍사스 칠드런스 하스피탈 아밀로이드 침착의 mri용 표적 조영제
WO2021163585A1 (en) 2020-02-12 2021-08-19 Texas Children's Hospital Targeted contrast agents for mri of alpha-synuclein deposition
US11779664B2 (en) 2020-02-12 2023-10-10 Texas Children's Hospital Targeted contrast agents for MRI of alpha-synuclein deposition
CN115970009A (zh) * 2023-02-08 2023-04-18 丽水市中心医院 Vhpk多肽修饰的荧光纳米脂质体给药系统、其制备方法及应用
CN116869938A (zh) * 2023-07-26 2023-10-13 安徽医科大学 一种1,2,4-噁二唑-吡啶脂质体及其制备方法和应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204085A (en) 1985-01-08 1993-04-20 Mallinckrodt Medical, Inc. Method for enhancing the safety of metal-ligand chelates as X-ray contrast agents
CN1148812A (zh) 1994-03-28 1997-04-30 尼科梅德成像有限公司 “脂质体”
US6071532A (en) 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof
JP4829454B2 (ja) 1999-11-30 2011-12-07 ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティ・オブ・アリゾナ 放射線感受性リポソーム
WO2002028441A2 (en) 2000-10-04 2002-04-11 California Institute Of Technology Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits
WO2002094191A2 (en) 2001-05-23 2002-11-28 New York University Detection of alzheimer's amyloid by magnetic resonance imaging
AU2003217950A1 (en) 2002-03-05 2003-09-22 Cleveland State University Agglomerated particles for aerosol drug delivery
EP1641742A4 (en) 2003-05-01 2006-11-29 Nst Neurosurvival Technologies COMPOUNDS BINDING SELECTIVELY TO MEMBRANES OF APOPTOTIC CELLS
US7208174B2 (en) 2003-12-18 2007-04-24 Hoffmann-La Roche Inc. Liposome compositions
US20100031378A1 (en) 2008-08-04 2010-02-04 Edwards Joel A Novel gene disruptions, compositions and methods relating thereto
US8357351B2 (en) 2004-04-21 2013-01-22 Ananth Annapragada Nano-scale contrast agents and methods of use
US7713517B2 (en) 2004-04-21 2010-05-11 Marval Biosciences, Inc. Compositions and methods for enhancing contrast in imaging
WO2006032705A2 (en) 2004-09-23 2006-03-30 Guerbet Contrast agents encapsulating systems for cest imaging
WO2007041855A1 (en) 2005-10-13 2007-04-19 Waratah Pharmaceuticals, Inc. Scyllo-inositol derivatives and their use in the treatment of diseases characterised by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence
WO2007048019A2 (en) 2005-10-20 2007-04-26 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
US20090123047A1 (en) 2007-03-21 2009-05-14 Yfantis Spyros A Method and system for characterizing prostate images
EP1982733A1 (en) 2007-04-17 2008-10-22 Bayer Schering Pharma Aktiengesellschaft Use of a contrast agent for magnetic resonance imaging of endoleaks
WO2008134618A2 (en) 2007-04-27 2008-11-06 The General Hospital Corporation Novel imaging tracers for early detection and treatment of amyloid plaques caused by alzheimer's disease and related disorders
CA2695204A1 (en) 2007-07-26 2009-01-29 Nanoscan Imaging, Llc Methods for imaging using improved nanoparticulate contrast agents
CA2708028A1 (en) 2007-12-05 2009-06-11 Marval Biosciences, Inc. Nano-scale contrast agents and methods of use
CN102037004A (zh) * 2008-01-08 2011-04-27 生物种属学股份公司 使用寡糖基转移酶的多肽的糖缀合
ITMI20081052A1 (it) 2008-06-10 2009-12-11 Univ Milano Bicocca Liposomi in grado di legare efficacemente il peptide beta-amiloide
WO2009152445A1 (en) 2008-06-13 2009-12-17 Marval Biosciences, Inc. Imaging of atherosclerotic plaques using liposomal imaging agents
WO2010017094A2 (en) 2008-07-31 2010-02-11 The General Hospital Corporation CURCUMIN DERIVATIVES FOR AMYLOID-β PLAQUE IMAGING
AR074760A1 (es) * 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
JP2012520898A (ja) 2009-03-19 2012-09-10 マーヴァル バイオサイエンシーズ，インコーポレイテッド 画像化におけるコントラスト強調のための組成物および方法
US20120263646A1 (en) 2009-10-15 2012-10-18 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
ES2526124T3 (es) * 2010-06-16 2015-01-07 Cymabay Therapeutics, Inc. Agonistas del receptor GPR120 y sus usos
AU2012223210B2 (en) 2011-03-02 2016-12-22 Board Of Regents Of The University Of Texas System Vesicle compositions
US9801957B2 (en) * 2011-04-06 2017-10-31 Ananth Annapragada Lipid-based nanoparticles
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
EP2756459B1 (en) 2012-01-20 2020-12-09 Ananth Annapragada Methods and compositions for objectively characterizing medical images
WO2013164763A2 (en) 2012-04-30 2013-11-07 Innovative Health Diagnostics A biological complex specific for alzheimer's disease detection in vitro and use thereof
AU2014240042C1 (en) * 2013-03-14 2019-09-05 Celltaxis, Llc Inhibitors of leukotriene A4 hydrolase
EP3542828A1 (en) 2014-10-08 2019-09-25 Texas Children's Hospital Mri imaging of amyloid plaque using liposomes

Also Published As

Publication number Publication date
EP3204051B1 (en) 2019-05-29
ES3032054T3 (en) 2025-07-15
CA2963941A1 (en) 2016-04-14
US20170080111A1 (en) 2017-03-23
US10537649B2 (en) 2020-01-21
JP2017532378A (ja) 2017-11-02
US20200179540A1 (en) 2020-06-11
EP4035688C0 (en) 2025-03-26
BR112017007238A2 (pt) 2018-01-16
AU2021203388B2 (en) 2024-05-30
KR20170103748A (ko) 2017-09-13
ES2743704T3 (es) 2020-02-20
HK1243335A1 (zh) 2018-07-13
EP3204051A4 (en) 2018-06-27
EP3204051A1 (en) 2017-08-16
AU2015330824A1 (en) 2017-05-25
EP4035688A1 (en) 2022-08-03
MX2017004695A (es) 2018-01-24
CN107106708B (zh) 2021-06-18
AU2021203388A1 (en) 2021-06-24
EP4035688B1 (en) 2025-03-26
MX371295B (es) 2020-01-24
KR102409017B1 (ko) 2022-06-16
US20160101197A1 (en) 2016-04-14
US20200069820A1 (en) 2020-03-05
CN107106708A (zh) 2017-08-29
US9744251B2 (en) 2017-08-29
US11141495B2 (en) 2021-10-12
EP3542828A1 (en) 2019-09-25
JP6505235B2 (ja) 2019-04-24
WO2016057812A1 (en) 2016-04-14

Similar Documents

Publication Publication Date Title
AU2021203388B2 (en) MRI Imaging Of Amyloid Plaque Using Liposomes
Tanifum et al. A novel liposomal nanoparticle for the imaging of amyloid plaque by magnetic resonance imaging
Moussaron et al. Ultrasmall nanoplatforms as calcium‐responsive contrast agents for magnetic resonance imaging
Kobayashi et al. Renal tubular damage detected by dynamic micro-MRI with a dendrimer-based magnetic resonance contrast agent
US20120258044A1 (en) Lipid-based nanoparticles
JP7114074B2 (ja) 画像化のためのニトロキシドを含むアミロイド結合剤およびその治療的使用
Cittadino et al. In vivo magnetic resonance imaging detection of paramagnetic liposomes loaded with amphiphilic Gadolinium (III) complexes: impact of molecular structure on relaxivity and excretion efficiency
JP7545393B2 (ja) 誤って折りたたまれたタンパク質を画像化するための機能化リポソーム
HK40010427A (en) Mri imaging of amyloid plaque using liposomes
BR112017007238B1 (pt) Composição lipossomal compreendendo um conjugado fosfolipídiopolímero-aromático e um agente potencializador de contraste de imagem de ressonância magnética não radioativo para geração de imagem de depósitos amiloides
US20230136718A1 (en) Functionalized liposomes for imaging misfolded proteins
HK1243335B (en) Mri imaging of amyloid plaque using liposomes
Rashid Lanthanide-Based Responsive Contrast Agents for Magnetic Resonance Imaging
Aime et al. Recent Developments of Contrast Agents, CEST and Low Fields
Song 2025 World Molecular Imaging Congress Program

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201001

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240926

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240926

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240926

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250929

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250929